<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Complications of Kawasaki disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Complications of Kawasaki disease</h1>
<div class="graphic"><div class="figure"><div class="ttl">Complications of Kawasaki disease</div><div class="cntnt"><table cellspacing="0"><colgroup span="2" width="25%"></colgroup><colgroup width="50%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1">Complication</td> <td class="subtitle1">Frequency</td> <td class="subtitle1">Comments</td> </tr> <tr class="divider_bottom divider_top"> <td><strong>Shock</strong></td> <td>Approximately 7%</td> <td> <ul> <li>Associated features: <ul> <li>Consumptive coagulopathy and cardiac abnormalities including impaired left ventricular systolic function, mitral regurgitation, and CAAs </li> <li>Higher C-reactive protein levels </li> <li>Less responsive to initial IVIG therapy and more commonly requires additional treatment </li> </ul> </li> </ul> </td> </tr> <tr class="divider_bottom"> <td><strong>Macrophage activation syndrome</strong></td> <td>Rare</td> <td> <ul> <li>Reported rarely in children with persistent fever after IVIG treatment </li> <li>Heralded by fall in ESR due to consumptive coagulopathy; also marked by ferritin levels &gt;5000 ng/mL </li> <li>Treatment with intravenous methylprednisolone, biologic response modifiers, or cyclosporine may be needed </li> </ul> </td> </tr> <tr class="divider_bottom"> <td colspan="3"><strong>Cardiac complications</strong></td> </tr> <tr class="divider_bottom"> <td class="indent1">CAAs (including dilation and/or aneurysm)</td> <td> <p>CAAs occur in approximately one-quarter of patients with KD in the IVIG era</p> Coronary artery aneurysms develop in approximately 4% of patients treated with IVIG</td> <td> <ul> <li>Risk factors associated with CAAs include: <ul> <li>Late diagnosis and delayed treatment with IVIG </li> <li>Age &lt;1 year or &gt;9 years </li> <li>Male sex </li> <li>Fever â‰¥14 days </li> <li>Serum sodium &lt;135 mEq/L, hematocrit &lt;35%, white cell count &gt;12,000/mm<sup>3</sup> </li> </ul> </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Ventricular dysfunction</td> <td>Occurs during the acute phase in one-quarter to one-half of patients with KD</td> <td> <ul> <li>In most cases, ventricular function is in only mildly or moderately depressed; severe ventricular dysfunction is rare </li> <li>Most commonly manifested by tachycardia and an S3 gallop; uncommonly may progress to heart failure </li> <li>May be caused by direct myocardial inflammation (ie, myocarditis) or from indirect negative inotropic effects of the systemic inflammatory response; ischemic cardiomyopathy may occur in patients after myocardial infarction </li> <li>Ventricular function usually improves rapidly after treatment with IVIG </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Valvular regurgitation</td> <td> <p>Mitral regurgitation is common in the acute phase</p> Aortic root dilation is common; aortic regurgitation is less common</td> <td> <ul> <li>Mitral regurgitation usually resolves in the convalescent phase </li> <li>Aortic root dilation may persist during the first year of follow-up </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Pericardial effusion</td> <td>Occurs in &lt;5% of patients</td> <td> <ul> <li>Very rarely causes tamponade </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Myocardial infarction</td> <td>Rare</td> <td> <ul> <li>Principal cause of mortality in KD </li> <li>Occurs only in patients with CAAs, most frequently in patients with giant CAAs </li> <li>Highest risk period is in the first 6 to 12 months, but risk continues into adulthood </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Arrhythmia</td> <td>Rare</td> <td> <ul> <li>Rarely occurs during the acute phase as a consequence of acute myocarditis </li> <li>Beyond the acute/subacute phase of illness, arrhythmia occurs chiefly as a consequence of myocardial ischemia or infarction </li> <li>Ventricular arrhythmias are likely indicators of underlying myocardial damage and are associated with increased risk of sudden death </li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Accelerated atherosclerosis</td> <td>Rare in patients without CAAs</td> <td> <ul> <li>Patients who have CAAs in the acute phase that persist in follow-up are considered to be at high risk for early atherosclerotic disease </li> <li>Patients who have CAAs in the acute phase that regress to normal during follow-up are considered to be at moderate risk for early atherosclerotic disease </li> <li>Patients who never had CAAs do not appear to be at increased risk for cardiovascular disease compared with the general pediatric population </li> </ul> </td> </tr> <tr class="divider_bottom"> <td><strong>Noncoronary vascular involvement</strong></td> <td> <p>Peripheral (rare)</p> Visceral (very rare)</td> <td> <ul> <li>Peripheral aneurysms may present as pulsatile masses in axillae or inguinal area </li> <li>Peripheral arterial obstruction can lead to ischemia and gangrene </li> <li>Most commonly occurs in children with severe KD, including those with large or giant CAAs </li> </ul> </td> </tr> <tr class="divider_bottom"> <td><strong>Urinary abnormalities and renal disease</strong></td> <td>Rare</td> <td> <ul> <li>Includes acute interstitial nephritis, mild proteinuria, acute kidney injury, hemolytic-uremic syndrome, and immune complex-mediated glomerulonephritis </li> <li>IVIG may also cause acute kidney injury, especially preparations using sucrose as a stabilizer </li> </ul> </td> </tr> <tr class="divider_bottom"> <td><strong>GI abnormalities</strong></td> <td>Mild GI manifestations occur commonly; severe involvement is rare</td> <td> <ul> <li>Mild GI involvement includes gallbladder hydrops, cholestasis, and paralytic ileus </li> <li>More severe involvement includes bile duct stenosis, appendicular vasculitis, hemorrhagic duodenitis, intestinal pseudo-obstruction, intussusception, and pancreatitis </li> </ul> </td> </tr> <tr> <td><strong>Sensorineural hearing loss</strong></td> <td>Rare</td> <td> <ul> <li>Usually transient </li> <li>Persistent sensorineural hearing loss is associated with delayed use of IVIG, prolonged thrombocytosis, anemia, and an elevated ESR </li> </ul> </td> </tr> </tbody></table></div><div class="graphic_footnotes">CAA: coronary artery abnormality; IVIG: intravenous immune globulin; ESR: erythrocyte sedimentation rate; KD: Kawasaki disease; GI: gastrointestinal.</div><div id="graphicVersion">Graphic 56475 Version 5.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
